MedPath

Effects of Almond Consumption on Quality of Sleep in Adults: A Randomised Controlled Trial.

Phase 3
Registration Number
CTRI/2023/02/049727
Lead Sponsor
Almond Board of California
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

PSQI score above 5 or ESS score equal to or above 10 upon screening.

Stable sleep habits for last 6 months (Self-reported)

Exclusion Criteria

Pregnant and lactating women.

Individuals allergic to almonds

Those who are suffering from sleep disorders: Chronic insomnia, Severe obstructive sleep apnea [apnea-hypopnea index (AHI) more than 30 episodes per hour], Restless leg syndrome, Parasomnias, Narcolepsy, Central apnea, Chronic fatigue syndrome, Fibromyalgia.

Night shift workers or Shift workers, varying work schedule.

Individuals suffering from/ suffered major depression, eating disorders and anxiety disorders.

Those on medication for sleep problems on a regular basis or taking melatonin supplements or on medication for diabetes.

Individuals with a history of prior diagnosis of stroke, myocardial infarction, interventional cardiology procedures, or other major mental illness or substance abuse as well as a history of cognitive impairment and major neurological disorders.

Advised special diets for the last six months.

Chronic pain conditions and taking sedatives, hypnotics, and painkillers regularly.

Substance abuse/smoking.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sleep efficiencyTimepoint: Baseline and Endpoint
Secondary Outcome Measures
NameTimeMethod
1.PSQI Scores <br/ ><br>2.REM latency (determined using a polysomnography <br/ ><br>3.Average sleep duration on a 7-day actigraphy report in a subset <br/ ><br>4.Proportion of time spent in REM sleep (6) which will be determined using a polysomnography <br/ ><br>5.ESS scores (43) which will determine improvement in daytime sleepiness. <br/ ><br>6.Quality of life: Performance on WHO Quality of life questionnaire (WHOQOL-BREF / WHOQOL-100). <br/ ><br>7.Levels of serotonin and melatonin. <br/ ><br>8.Inflammatory markers: TNF- alpha, IL-6 <br/ ><br>9.Neuroimmune regulation: Brain-Derived Neurotrophic Factor (BDNF) <br/ ><br>10.Lipid Profile, Fasting Blood Sugar, Post Prandial Blood Sugar and Hba1c. <br/ ><br>Timepoint: Baseline and Endpoint <br/ ><br>I.e Baseline and 8 weeks
© Copyright 2025. All Rights Reserved by MedPath